The dominant antibody type present in the blood of transplant recipients may indicate their likelihood of experiencing organ rejection, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings may help doctors identify patients who need aggressive treatments to safeguard the health of their new organ.

Through a collaboration of two transplant centers in France and the United States, Carmen Lefaucheur, MD, PhD, from the Saint-Louis Hospital, in Paris and his colleagues designed a study to determine the greatest risk for losing a transplanted organ based on the characteristics and function of donor-specific HLA antibodies. Their study included 125 kidney transplant patients with donor-specific anti-HLA antibodies detected in the first year post-transplant.

Read also: Immunosupressive drugs put transplant recipients at higher risk for aggressive melanoma 

The researchers found that the presence of certain donor-specific HLA antibodies—namely IgG3 and IgG4 subclasses–correlated with distinct patterns of antibody-mediated injury to the transplanted organ. Patients with mostly IgG3 donor-specific HLA antibodies had a higher likelihood of organ rejection soon after transplantation. If rejection occurred in those with mostly IgG4 antibodies, it was usually much later after transplantation.

“Our clinical investigation may help in the future to identify the patients that will require interventions to prevent the loss of a transplanted organ,” said Lefaucher. “Also, based on what we learned in this investigation, more studies will be initiated to further elucidate why some patients seem to maintain good outcomes while others demonstrate accelerated deterioration of the transplanted kidney in the presence of circulating donor-specific HLA antibodies.”

In an accompanying editorial, Stanley Jordan, MD, from Cedars-Sinai Medical Center noted that if the findings are supported by additional studies, they could be of great help in counseling patients and possibly avoiding costly immunotherapy to reduce what appear to be largely benign donor-specific HLA antibodies.

“Lefaucheur et al. are to be commended for this important work, which further enlightens our understanding of the natural history of immunodominant donor-specific HLA antibodies and their effect on allograft pathology and outcomes,” he wrote.